Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2031.
Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market Analysis and Insights
Age-Related Macular Degeneration (AMD) is an eye disease that may exacerbate over time. It is the leading cause of severe, permanent vision loss in people over age 60. Aging is one of the risk factors for the global incidence of early AMD. The world’s senior population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in elderly patients due to the rising chronic disease prevalence. The diagnosis of disease is possible at various stages, and genetic testing and retinal imaging are some of the techniques for detecting disease. The disease diagnosis is conducted mainly by optical imaging techniques and other standard processes.
There is no cure, but treatment for Age-Related Macular Degeneration (AMD) may slow the disease and keep you from severe vision loss. Age-Related Macular Degeneration (AMD) disease treatment generally includes drugs and diagnostic products. These techniques are used to reach the damaged part of the retina and allow the ease of treatment with therapies.
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market is expected to gain market growth in the forecast period of 2024 to 2031. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.8% in the forecast period of 2024 to 2031 and is expected to reach USD 22,951.90 million by 2031 from USD 13,677.02 million in 2023.
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sulentis, S.A., Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTX, Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., and lonis Pharmaceuticals, among others.
|
Market Definition
Anti-VEGF therapy halts abnormal blood vessel growth in the retina, a hallmark of conditions like age-related macular degeneration (AMD). By inhibiting the action of VEGF, these drugs prevent vessel leakage and damage to the central vision area (macula). Administered through eye injections, they slow vision loss and, in some cases, improve sight. This targeted treatment, pivotal in managing AMD, curtails the progression of the disease by impeding the growth of problematic blood vessels in the eye.
Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market Dynamics
This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Prevalence of Age-Related Macular Degeneration
The prevalence of vision-threatening diseases, such as glaucoma, cataracts, and age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. They stand out as the leading cause of blindness in the western working-age population. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth, which is driving the market growth.
- Increase in Strategic Initiative by Key Players
Association, the deal is used by the primary player to expand to a different region of the world along with the passing of technology from one player to others, increasing product approval and institutional research.
Various strategic initiatives are undertaken by market players, which involve partnership, product approval, and collaboration among others. These initiatives help them to strengthen their presence in the market and help them to promote market expansion. Moreover, some strategic initiatives increased demand for their products among several customers. Strategic initiatives such as collaboration, agreement, and signing sales agreements are expected to drive the market.
Opportunity
- Increasing Research and Development
Research and development is a prerequisite to modifying the treatment to treat different kinds of patients. The demand for Age-Related Macular Degeneration (AMD) treatment and procedures is increasing in every country. This is why companies are continuously focusing on research and development to successfully provide effective treatment to patients and healthcare workers.
The effects can be seen only for individuals in certain ways, including effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and permanent damage.
Challenges/ Restraints
- High Cost of Treatment and Procedures
The cost of the product plays a major factor in the market. In Age-Related Macular Degeneration (AMD) disease, it is generally observed that they are highly sophisticated, must be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, and with their expensive cost is a major concern in the current healthcare system.
Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage, leading to consuming a significant amount of healthcare resources. Most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment. But, this increases the possibilities and susceptibilities for new complications in the diagnosis, which demands additional healthcare resources and treatment, which is retraining the market growth.
- Limited Access to Treatment
The treatment of a disease directly depends upon the accessibility to the service available for that disease. The treatment rate of various types of Age-Related Macular Degeneration (AMD) diseases falls due to limited access to the hospitals and specialty clinics owing to the low income and limited resources among others.
An interview published in a report in 2019 with the major market players of the drug segment said that they face challenges in providing accessibility to the diagnosis product in the underdeveloped nation. About 285 million individuals worldwide are visually impaired; 80% of these people have curable eye disorders, but limited or no access to adequate care, products, or available technologies improves the prevalence of blindness and decreases the growth of the market.
Recent Developments
- In November 2023, Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology (AAO) annual meeting in San Francisco. This is an investor event where the companies try to attract investors, which helps the company increase the R&D
- In August 2023, Astellas Pharma Inc. announced that IZERVAY (avacincaptad pegol intravitreal solution) will be approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The rate of GA progression at the 12-month primary endpoint was statistically significantly (p<0.01) lower in two Phase 3 clinical trials with the novel complement C5 inhibitor IZERVAY, making it the only approved treatment for GA
- In November 2022, Sylentis, S.A., announced the recruitment of the first patient in a new phase II dose-finding trial with its compound SYL1801 for treating patients with Neovascular Age-Related Macular Degeneration (AMD). This is a randomized, double-blind, phase II trial with three parallel groups in which different dose levels will be administered to each group of subjects. The study has already started and will recruit 90 patients in different centers in several European countries. The trial's primary objective is to evaluate the effect on visual acuity of SYL1801 at all three doses, administered as one drop daily for six weeks in patients with neovascular AMD
- In May 2022, Adverum Biotechnologies, Inc. announced that the company had presented data at the American Society of Gene and Cell Therapy (ASGCT) 2022 annual meeting on the efficacy and safety outcome of ADVM-022 that supported Phase 2 development plans. This results in evaluating the ADVM-022 dose with new enhanced prophylactic steroid regimens in the subsequent clinical trial
- In March 2022, Novartis AG announced that Beovu (brolucizumab) 6 mg had been authorized by the European Commission (EC) to treat visual impairment caused by Diabetic Macular Edoema (DME). Beovu was initially approved by the EC in 20203 to treat wet age-related macular degeneration; the DME indication marks the medication's second approval. The ruling of the European Community (EC) applies to all 27 EU members and Liechtenstein, Iceland, and Norway
Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market Scope
The global Age-related macular degeneration (AMD) disease - anti VEGF market is categorized into three notable segments on the basis of type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Dry AMD
- Wet AMD
On the basis of type, the market is segmented into dry AMD and wet AMD.
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Home Healthcare
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
Distribution Channel
- Retail Sales
- Direct Tender
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
Regional Analysis/Insights: Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market is categorized into three notable segments on the basis of type, end user, and distribution channel.
The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa.
North America is expected to dominate global Age-Related Macular Degeneration (AMD) disease - anti VEGF due to rising prevalence of age-related macular degeneration. The U.S. is expected to dominate the North America region as it has the largest R&D spending globally and offers trade agreements with several countries, making it the largest market for consumer diagnosis and therapy products. China is expected to dominate the Asia-Pacific region due to the mass production of Age-related macular degeneration (AMD) disease - anti VEGF based products and increasing demand from emerging markets and expansion. Germany is expected to dominate the Europe region as it has the emerging reimbursement policies for the treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Share Analysis: Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major players operating in the global Age-related macular degeneration (AMD) disease - anti VEGF market are Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sylentis, S.A., Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTx Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., and Ionis Pharmaceuticals, among others.
SKU-